Taiho Draws From Hypomethylating Agent Experience In ASTX030 Program
The company said it plans to file for approval of the azacitidine/cedazuridine combination pill in myelodysplastic syndromes and chronic myelomonocytic leukemia.
Scrip - October 1, 2026

Execs On The Move: September 21–25, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - October 1, 2026

Lilly Reinforces Its Lead In Obesity, But There’s Still Room For New Arrivals
The US pharma giant’s winning streak continues but analysts are sure room remains in the obesity market for further innovation and new market entrants
Scrip - October 1, 2026

Abu Dhabi Bets On Screening And Diagnosis To Help Set The Gulf’s Fertility Benchmark
Abu Dhabi has set a 2030 roadmap to achieve ambitious global reproductive health ecosystem goals. Prevention and preconception health, genetic screening, fertility diagnosis and treatment and IVF are central elements. L.E.K. Consulting explained how Abu Dhabi is differentiating in its approach.
Medtech Insight - October 1, 2026

GLP-1s And CGMs Have High Untapped Combination Potential, Dexcom Says
State of Type 2 report shows the scale of the non-insulin market Dexcom wants to tap as it pushes for wider Medicare CGM reimbursement.
Medtech Insight - October 1, 2026

Scrip’s Guide To October 2026: ESMO, Q3s and Novel Anti-Infectives Approvals
October will bring plenty of oncology data from the ESMO meeting, while the Q3 reporting season gets underway, plus approval decisions are expected for a number of new anti-infectives.
Scrip - October 1, 2026

Samsung Bioepis And Teva Take Over The World With Multi-Product Biosimilar Deal
Samsung Bioepis and Teva deepen their partnership with a third development and commercialization deal – this time going global with six potential assets.
Generics Bulletin - October 1, 2026

Fresenius Secures Its Biosimilars Future With €750m mAbxience Buyout
Fresenius has taken full control of biosimilars developer mAbxience, striking a deal worth up to €750m to buy out the remaining 45% of the company, in a move that reflects both the increasing significance of biosimilars to Fresenius as well as the benefits of vertical integration.
Generics Bulletin - October 1, 2026

‘We Believe We Can Play A Larger Role’ – Orifarm Chief On ‘Ambitious’ Generics Expansion Plans
Orifarm has today unveiled a five-year plan that will see it push into new markets across Europe, with a “significant expansion in generics.” Chief executive Mads Fink Eriksen spoke to Generics Bulletin to offer further insights into the Danish firm’s strategy.
Generics Bulletin - October 1, 2026

On Your Radar? 4 Things To Look Out For In October
HBW Insight's 'On Your Radar?' highlights key developments and dates for your diary across both consumer health and cosmetics coming up in October. Earnings season, a cosmetic safety review and a delay to EU action on supplements feature in this month's issue.
HBW Insight - October 1, 2026

Regeneron, Sanofi Extend Dupixent Playbook With Four Next-Gen Immunology Antibodies
The expanded alliance sets the stage for a new wave of immunology assets as Sanofi and Regeneron look beyond Dupixent for future growth.
Scrip - October 1, 2026

Longevity Medicine Needs Clinical Framework, Not Just Better Tests Like GLP-1s
Hillary Lin, longevity doctor and CEO of CoreCare, offered her audience of peers a clinical framework and discerned hype from evidence-based care when it comes to extending people’s lifespan during the recent MVMNT Summit.
In Vivo - October 1, 2026

Fresenius Kabi Adds Direct-To-Payer Biosimilar Route With Waltz
Fresenius Kabi has added a direct-to-payer channel for three US biosimilars through Waltz Health, as the group also expands European IV fluids manufacturing with €54m of investment in Poland and Italy.
Generics Bulletin - October 1, 2026

What’s Next? Five Things To Look Out For In October
Generics Bulletin previews the most noteworthy and anticipated events for October 2026.
Generics Bulletin - October 1, 2026

33 Rx-To-OTC Switches On List For Next French President
French consumer health industry association NèreS and pharmacy unions FSPF and USPO have proposed switching 33 molecules from prescription-only to OTC status, as part of a push to make pharmacies the first port of call for everyday ailments ahead of France's 2027 presidential election.
HBW Insight - October 1, 2026

Pfizer’s Phase II Atopic Dermatitis Data Push Tilrekimig Into Pivotal AD, Asthma Trials
Mid-stage data presented at EADV support the targeting of IL-13, IL-4 and TSLP with Pfizer’s trispecific antibody, which the firm has moved into Phase III studies in two indications, including a head-to-head trial versus Sanofi’s IL-13/IL4 inhibitor Dupixent.
Scrip - October 1, 2026

NAD’s Stronger State AG Ties Give Self-Regulation New Accountability Muscle
The National Advertising Division discusses its new or strengthened partnerships with recipient organizations to improve the advertising challenge process as well as procedural changes during a Sept. 28 session of its ‘Ad Law In Motion” annual conference.
HBW Insight - October 1, 2026

Life’s ‘Easier’ Using US FDA Draft Guidance On Manufacturers’ Form 483 Inspection Responses
Draft guidance “talks about things that'll make your life easier and our lives easier,” says CDER Manufacturing Quality director Francis Godwin. Warnings increase every year to foreign OTC firms have been “making for other markets where there are no requirements.”
HBW Insight - October 1, 2026